CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
Nasal Glucagondrug
Likely dose
Nasal Glucagon 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02402933
NCT02402933Phase 3Completed
CompareCT.gov

A Multiple Center, Open Label, Prospective Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D

Eli Lilly and Company·interventional·Posted Mar 30, 2015·Updated Sep 23, 2019

In Brief

A Phase 3 clinical trial evaluating Nasal Glucagon for Hypoglycemia and Diabetes Mellitus. Completed, enrolled 26 participants across 3 sites.

Detailed Summary

Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia, Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 30, 2015
Enrollment StartMar 1, 2015
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.3 years ago

Interventions

Nasal Glucagondrug

3 mg nasal glucagon powder